EP Patent

EP3716952B1 — Dosage forms comprising a plasma kallikrein inhibitor

Assigned to Kalvista Pharmaceuticals Ltd · Expires 2022-01-05 · 4y expired

What this patent protects

Patent listed against Ekterly.

Drugs covered by this patent

Patent Metadata

Patent number
EP3716952B1
Jurisdiction
EP
Classification
—
Expires
2022-01-05
Drug substance claim
No
Drug product claim
No
Assignee
Kalvista Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.